YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer

Inclusion Criteria

• •Meets Western medical diagnostic criteria for extensive-stage small cell lung cancer and Chinese medicine diagnostic criteria for kidney deficiency with qi deficiency and stagnation of blood stasis;
• •Newly diagnosed extensive-stage small cell lung cancer patients who have not previously received Western medical antineoplastic therapy, with evaluable lesions;
• •Intended to receive ≥2 cycles of first-line immunotherapy plus platinum-based chemotherapy plus etoposide;
• •No concurrent or prior history of other primary malignancies;
• •Aged ≥18 years with an estimated survival period of ≥3 months;
• •Karnofsky Performance Status (KPS) ≥60 points;
• •Normal cognitive function sufficient to complete questionnaires;
• •Voluntary acceptance of the study treatment regimen and signing of informed consent.